Literature DB >> 16113433

Effects of inhaled corticosteroids on pathology in asthma and chronic obstructive pulmonary disease.

Pascal Chanez1, Arnaud Bourdin, Isabelle Vachier, Philippe Godard, Jean Bousquet, A M Vignola.   

Abstract

The effects of inhaled corticosteroids (ICSs) have been investigated in asthma and chronic obstructive pulmonary disease (COPD) using endobronchial biopsies. In asthma, most studies have shown reductions in infiltrating eosinophils, mast cells, and T lymphocytes. Cell-associated mediators, such as cytokines derived from type 2 T-helper lymphocytes, are decreased as assessed by immunostaining and molecular biology techniques. More recently, attention has been devoted to the effect of ICSs on structural changes. In asthma, ICSs have been shown in some studies to affect collagen deposition (size of the reticular basement membrane), the number of vessels, or epithelial integrity. The correlations between those findings and various clinical and functional outcomes are far from clear. A long-term study has shown a decrease in the basement membrane size in a group of patients with asthma treated according to their level of airway hyperreactivity. In COPD, ICSs generally do not decrease neutrophils, macrophages, and CD8(+) T lymphocytes. The effects of these drugs on structural changes in COPD have not been investigated extensively. Long-term prospective studies are needed to demonstrate the potential for ICSs to affect the natural history of chronic bronchial diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16113433     DOI: 10.1513/pats.200402-006MS

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  9 in total

1.  Can GPCRs Be Targeted to Control Inflammation in Asthma?

Authors:  Pawan Sharma; Raymond B Penn
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  How does race and ethnicity effect the precision treatment of asthma?

Authors:  Ellen Zhang; Albert M Levin; L Keoki Williams
Journal:  Expert Rev Precis Med Drug Dev       Date:  2019-11-14

3.  Airway and lung pathology due to mucosal surface dehydration in {beta}-epithelial Na+ channel-overexpressing mice: role of TNF-{alpha} and IL-4R{alpha} signaling, influence of neonatal development, and limited efficacy of glucocorticoid treatment.

Authors:  Alessandra Livraghi; Barbara R Grubb; Elizabeth J Hudson; Kristen J Wilkinson; John K Sheehan; Marcus A Mall; Wanda K O'Neal; Richard C Boucher; Scott H Randell
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

4.  Blood neutrophil activation markers in severe asthma: lack of inhibition by prednisolone therapy.

Authors:  Bhupinder S Mann; Kian Fan Chung
Journal:  Respir Res       Date:  2006-04-06

5.  A randomized controlled trial of inhaled corticosteroids (ICS) on markers of epithelial-mesenchymal transition (EMT) in large airway samples in COPD: an exploratory proof of concept study.

Authors:  Sukhwinder Singh Sohal; Amir Soltani; David Reid; Chris Ward; Karen E Wills; H Konrad Muller; Eugene Haydn Walters
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-05-27

6.  The effects of inhaled corticosteroids on growth in children.

Authors:  Jim Philip
Journal:  Open Respir Med J       Date:  2014-12-31

Review 7.  The use of inhaled corticosteroids in pediatric asthma: update.

Authors:  Elham Hossny; Nelson Rosario; Bee Wah Lee; Meenu Singh; Dalia El-Ghoneimy; Jian Yi Soh; Peter Le Souef
Journal:  World Allergy Organ J       Date:  2016-08-12       Impact factor: 4.084

8.  Changes in airway histone deacetylase2 in smokers and COPD with inhaled corticosteroids: a randomized controlled trial.

Authors:  Sukhwinder Singh Sohal; David Reid; Amir Soltani; Steven Weston; Hans Konrad Muller; Richard Wood-Baker; Eugene Haydn Walters
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

9.  The effects of budesonide on angiogenesis in a murine asthma model.

Authors:  Yan Sun; Jinrong Wang; Huabing Li; Lifeng Sun; Yulin Wang; Xiuzhen Han
Journal:  Arch Med Sci       Date:  2013-02-18       Impact factor: 3.318

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.